| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050725966 |
| P356 | DOI | 10.2165/00019053-200018060-00006 |
| P698 | PubMed publication ID | 11227397 |
| P2093 | author name string | Markham A | |
| Adkins JC | |||
| P2860 | cites work | Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials | Q24563083 |
| Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells | Q28119034 | ||
| Changing prevalence of allergic rhinitis and asthma | Q33545607 | ||
| The natural history of asthma in adults: the problem of irreversibility | Q33592145 | ||
| Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma | Q33649671 | ||
| Compliance in asthma | Q33798272 | ||
| Epidemiology of asthma: the year in review | Q33802188 | ||
| Improving patient compliance with asthma therapy | Q33861307 | ||
| Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma | Q34112937 | ||
| Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma | Q34126829 | ||
| Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease | Q34653402 | ||
| Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study | Q36244470 | ||
| Changing prevalence of asthma in Australian children | Q36885947 | ||
| Patterns of asthma mortality in Philadelphia from 1969 to 1991. | Q39391349 | ||
| The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists | Q39447522 | ||
| Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma | Q39455703 | ||
| United HealthCare of Illinois: working to improve asthma care | Q39520594 | ||
| Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma | Q40388214 | ||
| A national estimate of the economic costs of asthma | Q40881742 | ||
| The costs of asthma | Q41050636 | ||
| National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care | Q41114417 | ||
| An economic evaluation of asthma in the United States | Q41120870 | ||
| Asthma: from childhood to adulthood | Q41340900 | ||
| Stabilization of asthma mortality | Q41436218 | ||
| Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma | Q41563083 | ||
| Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma | Q46957858 | ||
| Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease | Q50596117 | ||
| Costs of asthma according to the degree of severity. | Q50637174 | ||
| Determining a minimal important change in a disease-specific Quality of Life Questionnaire. | Q51136958 | ||
| Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. | Q53624302 | ||
| A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma | Q57956064 | ||
| Measuring quality of life in asthma | Q70642896 | ||
| Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group | Q71060995 | ||
| Patient factors and compliance with asthma therapy | Q73398073 | ||
| Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma | Q73398082 | ||
| Symptoms, quality of life, and health service contact among young adults with mild asthma | Q73445002 | ||
| Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma | Q73445017 | ||
| The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991 | Q73718003 | ||
| Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial | Q73900956 | ||
| Low-dose inhaled corticosteroids and the prevention of death from asthma | Q74098990 | ||
| Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma | Q74112300 | ||
| Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group | Q74112302 | ||
| Trends in the cost of illness for asthma in the United States, 1985-1994 | Q74308240 | ||
| The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults | Q74537349 | ||
| Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers | Q77321212 | ||
| Reversing the trend: reducing the prevalence of asthma | Q77807760 | ||
| P433 | issue | 6 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 591-608 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma | |
| P478 | volume | 18 |
| Q35826295 | Budesonide/formoterol: a review of its use in asthma |
| Q51239172 | Burden of illness of patients with allergic asthma versus non-allergic asthma. |
| Q37609214 | Cost-effectiveness of Advair: fluticasone propionate and salmeterol combination |
| Q24241308 | Fluticasone versus placebo for chronic asthma in adults and children |
| Q24245407 | Fluticasone versus placebo for chronic asthma in adults and children |
| Q44229943 | Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control |
| Q35213448 | Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma |
| Q24246441 | Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid |
| Q57493273 | Omalizumab for Severe Asthma: Beyond Allergic Asthma |
| Q44597029 | Seizure‐free Days Observed in Randomized Placebo‐controlled Add‐on Trials with Levetiracetam in Partial Epilepsy |
Search more.